Inhalant allergen testing identifies and quantifies airborne allergens—such as dust mites, pollen, animal dander, mold spores, and cockroach allergens—that trigger allergic rhinitis, asthma, and other IgE-mediated disorders. Accredited third-party laboratories offer comprehensive inhalant allergen detection services covering serum specific IgE immunoassays, environmental dust analysis, and bioaerosol monitoring to support clinical diagnosis, indoor air quality assessment, and product performance claims. This technical article explains the tested sample types, allergen panels, analytical methods, applicable standards, and practical applications of inhalant allergen testing.
Technical Overview
Inhalant allergens, also known as aeroallergens, are substances suspended in air or settled in dust that enter the human body through the respiratory tract, conjunctiva, or skin contact and induce IgE-mediated type I hypersensitivity reactions. Common sources include house dust mites, animal dander, pollen grains, fungal spores, and cockroach-derived proteins. In sensitized individuals, re-exposure to these allergens releases inflammatory mediators that manifest as allergic rhinitis, allergic conjunctivitis, bronchial asthma, and atopic dermatitis, making accurate allergen identification essential for avoidance strategies and allergen immunotherapy decisions.
Inhalant allergen testing encompasses three complementary technical approaches: in vivo skin testing performed under clinical supervision, in vitro serological testing that measures total and allergen-specific IgE antibodies in patient serum, and environmental analysis that quantifies allergen burden in dust, air, and product samples. Accredited third-party laboratories performing these tests operate in accordance with ISO/IEC 17025 general requirements for laboratory competence, calibrate IgE assays against WHO International Standards, and apply allergen nomenclature published by the International Union of Immunological Societies (IUIS).
Results are typically reported in kU/L or kUA/L for serum antibodies and in micrograms of allergen per gram of dust for environmental samples, providing quantitative data suitable for diagnosis, risk assessment, and regulatory or commercial claims support.
Testing Samples
Human Serum and Plasma Samples
Venous blood (typically 2–5 mL) is collected into serum separator or EDTA tubes for total IgE and specific IgE analysis. Unlike skin prick testing, serological testing does not require fasting and is not significantly affected by antihistamine medication, making it suitable for infants, pregnant women, elderly patients, and individuals with extensive skin conditions or dermatographism. Samples remain stable during refrigerated transport and can be batched for multi-allergen panel testing from a single draw.
Environmental Dust Samples
Settled dust is collected by standardized vacuum sampling from mattresses, pillows, carpets, upholstered furniture, and floors using defined sampling areas and flow rates. The dust is sieved through fine mesh to remove coarse debris, weighed, and extracted in buffered solution prior to immunoassay. Dust analysis reflects long-term allergen accumulation and is the reference matrix for assessing mite, pet, and cockroach allergen reservoirs in indoor environments.
Air Samples
Airborne allergens and bioaerosols are captured using volumetric samplers, cascade impactors, filtration cassettes, or liquid impingers operated over defined time periods and flow rates consistent with ISO 16000 series indoor air sampling guidance. Air samples support pollen and fungal spore enumeration by microscopy as well as immunological or molecular quantification of airborne allergen concentrations in residential, office, school, and healthcare settings.
Surface Swab and Consumer Product Samples
Surface swabs, textile cuttings from bedding and upholstered goods, anti-mite fabric specimens, air purifier filters, vacuum cleaner exhaust captures, and toy surface samples can be submitted for allergen residue testing. These matrices are used to verify allergen-barrier performance, assess cleaning efficacy, and substantiate marketing claims for anti-allergen products.
Testing Items
Comprehensive inhalant allergen panels are organized by allergen source. Typical test items offered by accredited third-party laboratories include:
- House dust mites: Dermatophagoides pteronyssinus, Dermatophagoides farinae, Blomia tropicalis, Euroglyphus maynei, and molecular components Der p 1, Der p 2, Der p 10, Der f 1, and Der f 2.
- Animal dander and epithelia: cat dander (Fel d 1), dog dander (Can f 1, Can f 5), horse dander, rabbit epithelium, guinea pig epithelium, hamster epithelium, and mouse and rat urinary proteins for laboratory animal allergy.
- Fungal and mold allergens: Alternaria alternata (Alt a 1), Cladosporium herbarum, Aspergillus fumigatus, Penicillium chrysogenum, Chaetomium globosum, and Candida albicans.
- Tree pollen: birch (Bet v 1), oak, plane tree, cypress, willow, poplar, elm, Japanese cedar (Cry j 1), and olive (Ole e 1).
- Grass pollen: timothy (Phl p 1, Phl p 5), Bermuda grass, ryegrass, Kentucky bluegrass, and cultivated rye.
- Weed pollen: mugwort (Art v 1), ragweed (Amb a 1), plantain, goosefoot, and Russian thistle.
- Insect allergens: German cockroach (Bla g 1, Bla g 2) and American cockroach (Per a 1) allergens, as well as midge and moth-derived inhalant allergens.
- Other inhalant sources: house dust extract and natural rubber latex (Hev b components).
- Supporting serology: total IgE (tIgE) for atopy screening and, where required, allergen-specific IgG4 for immunotherapy follow-up.
Testing Methods
Skin Prick Testing
Skin prick testing is the primary in vivo diagnostic method, in which standardized allergen extracts are introduced into the skin surface and the resulting wheal-and-flare response is measured after 15–20 minutes, with histamine serving as the positive control. Although performed clinically rather than as a laboratory service, third-party laboratories frequently prepare, characterize, and quality-control the standardized extracts used in these procedures.
Total IgE and Specific IgE Immunoassays
Serum specific IgE is quantified using fluorescence enzyme immunoassay (FEIA), chemiluminescence immunoassay (CLIA), or enzyme-linked immunosorbent assay (ELISA) platforms, with results reported in kUA/L and graded into classes 0 through 6, where values of 0.35 kUA/L or above indicate sensitization. Total IgE is measured by the same immunochemical platforms and calibrated against WHO International Standards to ensure metrological traceability.
Immunoblot and Line-Blot Assays
Line immunoblot technology immobilizes multiple purified or recombinant allergen lines on a membrane strip, allowing simultaneous semi-quantitative screening of twenty or more inhalant and food allergens from a small serum volume. This format is widely used for cost-effective regional panel screening and pediatric initial work-ups.
Component-Resolved Diagnostics
Component-resolved diagnostics (CRD) uses recombinant or highly purified natural allergen molecules, either in singleplex immunoassays or multiplex microarray formats, to distinguish genuine species-specific sensitization from cross-reactivity. Key inhalant components such as Der p 1, Der p 2, Der p 10, Fel d 1, Bet v 1, Phl p 1, Amb a 1, and Alt a 1 enable precise assessment of cross-reactive carbohydrate determinants, pan-allergens such as tropomyosin and profilin, and candidate markers for allergen immunotherapy selection.
Basophil Activation Test
The basophil activation test (BAT) evaluates functional allergic responses by flow cytometric detection of CD63 or CD203c expression on patient basophils after ex vivo allergen challenge. BAT provides complementary information when skin tests and specific IgE results are discordant with the clinical history.
Environmental Allergen Quantification
Allergen burden in dust, air, and product extracts is quantified by two-site sandwich ELISA or multiplexed suspension array assays targeting major indoor allergens including Der p 1, Der f 1, Der p 2, Fel d 1, Can f 1, Bla g 1, and Bla g 2. Results in micrograms of allergen per gram of dust are compared against published health-based thresholds for sensitization and symptom exacerbation risk.
Molecular and Microbiological Identification
Quantitative real-time PCR identifies mite species and fungal taxa in environmental samples with high sensitivity, while light microscopy and gravimetric spore counting enumerate pollen grains and fungal spores in air samples. Culture-based mycological examination complements molecular methods where viable fungal identification is required.
Quality Assurance
All analytical workflows are validated under ISO/IEC 17025 quality management systems, with method validation covering precision, linearity, limit of detection, and accuracy. Laboratories participate in inter-laboratory proficiency testing programs, use calibrated traceable reference materials, and follow CLSI immunoassay guidance and applicable national standards (GB, EN, JIS) where relevant to ensure reproducible, defensible results.
Applications
- Clinical allergy diagnosis: identification of causative allergens in patients with allergic rhinitis, asthma, allergic conjunctivitis, and atopic dermatitis to guide avoidance measures and pharmacotherapy.
- Allergen immunotherapy support: selection and monitoring of patients undergoing subcutaneous or sublingual immunotherapy, including specific IgG4 follow-up testing.
- Indoor environmental assessment: evaluation of mite, pet, mold, and cockroach allergen reservoirs in homes, schools, hotels, offices, and healthcare facilities, with remediation verification after cleaning or intervention.
- Product development and claims substantiation: performance verification of allergen-barrier bedding, anti-mite textiles, air purifiers, vacuum cleaners, HVAC filtration, and surface treatments.
- Occupational health: monitoring of laboratory animal allergens, latex aeroallergens, and enzyme exposures in workplace exposure assessment programs.
- Epidemiological and academic research: population-based sensitization mapping, aeroallergen surveillance, and clinical study support under standardized protocols.
FAQ
What is the difference between skin prick testing and serum specific IgE testing?
Skin prick testing is an in vivo procedure that measures immediate skin reactivity to allergen extracts and requires discontinuation of antihistamines, whereas serum specific IgE testing is an in vitro laboratory assay performed on a blood sample that is unaffected by antihistamines and can be safely used in patients with severe skin disease, infancy, pregnancy, or high anaphylaxis risk. The two methods are complementary and are often used together with the clinical history.
Does a positive specific IgE result confirm clinical allergy?
A positive result demonstrates sensitization, meaning IgE antibodies are present, but clinical allergy also requires symptom correlation upon exposure. Component-resolved diagnostics and basophil activation testing help refine the assessment when sensitization and symptoms do not align.
What do IgE antibody classes 0 to 6 mean?
Specific IgE results are commonly graded from class 0 (below 0.35 kUA/L, no detectable antibody) to class 6 (100 kUA/L or above, very high level), with higher classes indicating greater antibody concentration. Class levels guide interpretation but must be integrated with clinical presentation, as antibody quantity alone does not strictly predict symptom severity.
How are dust samples collected for environmental allergen testing?
Settled dust is collected by vacuuming a defined surface area, such as the entire upper mattress surface or a one-square-meter carpet zone, using a standardized collection nozzle and sock for a fixed time interval. Sampling kits and detailed protocols are provided by accredited third-party laboratories to ensure representative, comparable results.
Can inhalant allergen testing be performed on young children?
Yes, serum specific IgE testing requires only a small blood volume and carries no exposure risk, making it appropriate for infants and young children. A reduced regional panel focused on mites, animal dander, mold, and locally relevant pollens is typically recommended for pediatric patients.
How long does testing take and when should retesting be considered?
Standard panel results are typically available within three to seven working days after sample receipt, while component-resolved and multiplex testing may require additional time. Retesting is generally considered one to two years after diagnosis, after immunotherapy courses, or when exposure patterns or symptoms change significantly.